|Principal Investigator/ Physician||Thomas W. Butler, MD|
|Protocol No.||ECOG 3612|
|Status||Closed to Enrollment|
|Sponsor||Eastern Cooperative Oncology Group|
|Contact Email||MCI Clinical Trials|
Protocol Title: "A randomized phase II of Ipilimumab with or without Bevacizumab in patients with unresectable Stage III or Stage IV Melanoma."
Inclusion criteria: ECOG 0-1. Untreated or previously received one treatment for measurable unresectable stage III or stage IV melanoma. Patients with BRAF mutation must be known. Prior treatment must be completed >4 weeks prior to randomization.
Exclusion criteria: Patients with active infection, prior hypertensive crisis, CHF, history of MI or unstable angina, stroke or transient ischemic attack, peripheral vascular disease, bleeding diathesis or coagulopathy, surgical procedures within 4 weeks of randomization, biopsy or minor surgical procedure within 7 days of randomization, history of non-healing wound or ulcer.
Clinical Trails.Gov Link: https://clinicaltrials.gov/ct2/show/NCT01950390?term=ECOG+3612&rank=1
© 2018 USA Health System